Oxford Biomedica plc

BATS-CHIXE:OXBL Stock Report

Market Cap: UK£434.6m

Oxford Biomedica Valuation

Is OXBL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OXBL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OXBL (£4.14) is trading below our estimate of fair value (£18.01)

Significantly Below Fair Value: OXBL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXBL?

Key metric: As OXBL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OXBL. This is calculated by dividing OXBL's market cap by their current revenue.
What is OXBL's PS Ratio?
PS Ratio4.5x
SalesUK£97.28m
Market CapUK£434.61m

Price to Sales Ratio vs Peers

How does OXBL's PS Ratio compare to its peers?

The above table shows the PS ratio for OXBL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.4x
BVXP Bioventix
14.4xn/aUK£195.7m
GNS Genus
1.7x3.5%UK£1.1b
AVCT Avacta Group
7.9x0.4%UK£170.1m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
OXBL Oxford Biomedica
4.5x21.0%UK£434.6m

Price-To-Sales vs Peers: OXBL is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (6.2x).

Price to Sales Ratio vs Industry

How does OXBL's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
OXBL Oxford Biomedica
 4.5x21.0%US$547.42m
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$553.81m
No. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a37.4%
OXBL Oxford Biomedica
 4.5x93.2%US$547.42m
No more companies

Price-To-Sales vs Industry: OXBL is good value based on its Price-To-Sales Ratio (4.5x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is OXBL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXBL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: OXBL is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OXBL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£4.18
UK£5.13
+22.6%
22.2%UK£7.40UK£3.80n/a8
Nov ’25UK£4.02
UK£5.17
+28.8%
23.3%UK£7.40UK£3.80n/a7
Oct ’25UK£3.81
UK£4.96
+30.5%
28.4%UK£7.40UK£3.05n/a7
Sep ’25UK£3.38
UK£4.74
+40.1%
34.7%UK£7.40UK£2.50n/a7
Aug ’25UK£3.71
UK£4.49
+21.2%
36.8%UK£7.40UK£2.50n/a8
Jul ’25UK£2.99
UK£4.49
+50.1%
36.8%UK£7.40UK£2.50n/a8
Jun ’25UK£3.32
UK£4.49
+35.2%
36.8%UK£7.40UK£2.50n/a8
May ’25UK£2.87
UK£4.18
+45.6%
45.6%UK£7.40UK£1.80n/a8
Apr ’25UK£2.02
UK£4.15
+106.1%
46.2%UK£7.40UK£1.80n/a8
Mar ’25UK£1.70
UK£4.24
+149.7%
41.7%UK£7.20UK£2.10n/a8
Feb ’25UK£1.78
UK£4.24
+137.7%
41.7%UK£7.20UK£2.10n/a8
Jan ’25UK£2.16
UK£4.24
+96.1%
41.7%UK£7.20UK£2.10n/a8
Dec ’24UK£1.67
UK£4.33
+159.6%
40.0%UK£7.20UK£2.65n/a7
Nov ’24UK£2.05
UK£7.14
+248.9%
93.4%UK£24.00UK£2.65UK£4.028
Oct ’24UK£3.05
UK£7.50
+145.8%
89.9%UK£24.00UK£2.65UK£3.818
Sep ’24UK£3.29
UK£9.22
+180.7%
62.9%UK£24.00UK£3.65UK£3.389
Aug ’24UK£4.49
UK£9.30
+107.2%
61.6%UK£24.00UK£3.65UK£3.719
Jul ’24UK£4.21
UK£9.29
+121.0%
61.6%UK£24.00UK£3.65UK£2.999
Jun ’24UK£4.56
UK£10.89
+138.9%
51.9%UK£24.00UK£5.25UK£3.327
May ’24UK£4.30
UK£11.48
+166.7%
52.2%UK£24.00UK£5.25UK£2.876
Apr ’24UK£4.31
UK£10.65
+147.1%
57.5%UK£24.00UK£3.60UK£2.027
Mar ’24UK£5.60
UK£10.65
+90.2%
57.5%UK£24.00UK£3.60UK£1.707
Feb ’24UK£4.24
UK£10.65
+151.5%
57.5%UK£24.00UK£3.60UK£1.787
Jan ’24UK£4.44
UK£10.65
+140.1%
57.5%UK£24.00UK£3.60UK£2.167
Dec ’23UK£4.05
UK£10.65
+163.3%
57.5%UK£24.00UK£3.60UK£1.677
Nov ’23UK£3.36
UK£13.44
+300.5%
45.8%UK£24.00UK£5.25UK£2.056

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€821.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

hVIVO

UK£155.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%